Core Viewpoint - The announcement reveals that major shareholders of Aorede (600666) have had their shares frozen by the Harbin Intermediate People's Court due to ongoing debt disputes and performance compensation obligations, impacting the company's stock and governance structure [1][2][3] Group 1: Shareholder Actions - Major shareholders Chu Shuxia and Zuo Hongbo have had a total of 235 million shares frozen, representing 8.52% of the company's total equity, with the freeze starting on September 12, 2025, for a period of 36 months [1] - The frozen shares include 151 million shares held by Chu Shuxia and 84.27 million shares held by Zuo Hongbo, accounting for 5.47% and 3.05% of the total equity, respectively [1] Group 2: Performance Compensation Obligations - The performance compensation obligation for Zuo Hongbo and Chu Shuxia amounts to 391 million shares, with the company applying for enforcement through the Harbin Intermediate People's Court [2] - Due to other debt disputes, the recovery of performance compensation shares and cash remains highly uncertain [2] Group 3: Historical Context and Financial Performance - Aorede's acquisition of 100% equity from Southwest Pharmaceutical in 2015 involved a share swap and a cash component of 3.338 billion yuan, leading to Zuo Hongbo and Chu Shuxia becoming controlling shareholders [2] - Aorede committed to a cumulative net profit of no less than 1.216 billion yuan from 2015 to 2017, but the actual net profit was only 648 million yuan, achieving a completion rate of 53% [3] - Due to underperformance, Zuo Hongbo and Chu Shuxia are liable for 99.52% of the compensation obligations, which may lead to forced judicial auction of their shares [3]
奥瑞德:原实控人所持公司2.35亿股股份被轮候冻结